Actively Recruiting
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
Led by Yan Zhang, MD · Updated on 2023-12-20
30
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
Sponsors
Y
Yan Zhang, MD
Lead Sponsor
P
Peking University Third Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a prospective, single-arm, phase II study, and the purpose of this study is to evaluate the efficacy and safety of Pola-R2 regimen in newly diagnosed elderly diffuse large B cell lymphoma classified into un-fit or frail group by comprehensive geriatric assessment(CGA).
CONDITIONS
Official Title
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient volunteered and signed informed consent
- Histopathologically confirmed diffuse large B cell lymphoma (DLBCL) and treatment naive (except corticosteroids alone)
- Age 70 years or older and classified as un-fit or frail by comprehensive geriatric assessment
- Adequate organ function and bone marrow reserve
You will not qualify if you...
- Having another active malignancy besides lymphoma
- Active hepatitis B virus (HBV) infection
- Unstable systemic disease including active infection (other than local), severe cardiac, liver, kidney, or metabolic disease requiring therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
W
Wei Wang, MD
CONTACT
Z
Zhaohui Zhu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here